Day One Biopharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 62.41 million compared to USD 42.39 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.59 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.61 USD | -2.40% |
|
-1.25% | -13.63% |
Jun. 12 | Day One Biopharmaceuticals Insider Sold Shares Worth $378,588, According to a Recent SEC Filing | MT |
Jun. 12 | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.63% | 1.1B | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- DAWN Stock
- News Day One Biopharmaceuticals, Inc.
- Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024